dactinomycin has been researched along with aclacinomycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayakawa, O; Kudo, R; Takehara, M | 1 |
| Duverger, A; Jones, J; Kappes, J; Kutsch, O; Shishido, T; Wagner, F; Wolschendorf, F | 1 |
2 other study(ies) available for dactinomycin and aclacinomycin
| Article | Year |
|---|---|
[Experimental and clinical study on chemotherapy for cervical adenocarcinoma].
Topics: Aclarubicin; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dactinomycin; Drug Administration Schedule; Etoposide; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mitomycin; Neoplasm Transplantation; Uterine Cervical Neoplasms | 1995 |
Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation.
Topics: Aclarubicin; Anti-HIV Agents; Cell Differentiation; Cell Line; Dactinomycin; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; T-Lymphocytes; Virus Activation; Virus Latency | 2012 |